Anzeige
Mehr »
Lynx Broker
Login
Freitag, 18.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
DoTeva's $15B free drug opioid settlement might be a great deal in the long run: analyst
DoCSL: Former exec stole 'thousands' of secret files before joining rival Pharming
DoJ&J, Amarin cardiovascular drugs are cost-effective, ICER says-but there's a catch
DoLawsuit-ridden J&J tumbles in annual listing of best global brands
DoNew CDMO, backed by private equity player, to manufacture biologics
MiAnother hit for AbbVie: Unexpected $673M Irish tax bill adds to Allergan merger woes
MiRoche limits biosim damage to cancer blockbusters, but it's still early, execs warn
MiTeva, J&J make multibillion-dollar settlement offers as opioid trial gets going
MiNovo builds $40M wastewater plant then gives it away
MiSanofi aims to save 1,100 jobs in Bangladesh by selling its local stake: report
MiFDA tags Torrent as key offender in production of tainted blood pressure meds
MiJ&J wins reversal of $110M talc verdict, its 4th appeals win in Missouri
DiGilead elevates M&A architect Dickinson to CFO. Could more deals be next?
DiPfizer scrambles to fill void after Teva stops making chemo drug often given to children
DiJohnson & Johnson's bridging its $2B patent cliff gap, with help from Stelara, Darzalex
DiMerck and the machine: German pharma tests real-time platform to forestall drug shortages
DiSanofi U.S. plant sets new bar for biologics production
DiTakeda wraps 30 emerging markets drugs in $200M selloff to Swiss pharma Acino
MoAstraZeneca got past FluMist's efficacy woes, but now it's plagued by production problems
MoJ&J, Bayer's Xarelto scores FDA nod to treat acutely ill patients during and after hospitalization
MoPurdue, billionaire founders win temporary reprieve from lawsuits in hopes of reaching deal
MoFiercePharmaPolitics-PhRMA attacks Pelosi plan as CBO says it would lower spending; drugmakers raise more prices
11.10.Lilly scores FDA nod for new migraine drug Reyvow
11.10.ICER says AbbVie's Rinvoq for RA may be cost-effective but still questions the value of JAK class
11.10.Johnson & Johnson, besieged by lawsuits, could be a steal for investors: analyst